San Diego — Ridge Diagnostics, Inc., a neurodiagnostic company, has announced that the Scientific Program Committee of the American Psychiatric Association has accepted for presentation their scientific and clinical report entitled, "Assessment of a Biomarker Panel for Major Depressive Disorder in a Community Based Study."
The presentation will be made by Dr. Perry Renshaw, Director of Magnetic Resonance, Utah Brain Institute, Professor of Psychiatry, University of Utah School of Medicine, Salt Lake City, Utah.
A blood test, for the first time, provides clinicians with biological information derived from physiological changes associated with MDD. By adding an objective, biological basis, the blood test results are intended to augment the current tools used for neuropsychiatric diagnosis and patient management.
"The data being presented a the APA meeting validates the clinical importance of the MDDScore in community-based psychiatric practices," stated Lonna J. Williams, CEO of Ridge Diagnostics. "The outcomes prove that accurate diagnosis can be difficult, even in psychiatric practices, and that patients both desire and respond to blood tests for mental health purposes as they are accustomed to blood tests for their medical care."
Dr. Renshaw will present the information at the APA Annual Meeting in Honolulu, Hawaii, May 14-18, 2011.